Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Precision Medicine
Identification of relevant biomarkers, and development of assays to quantify them, are increasingly important in this era of personalised drug development. This is the core of translational science.
Precision medicine is an important area of clinical and translational science aimed at tailoring therapies to patients based on a combination of molecular and clinical information. Precision medicine is often described as finding the right drug for the right patient at the right time. One of the foundations of any precision medicine approach is identification of biomarkers, which may be defined as objective indicators of biological states. Examples of biomarkers range from measurable clinical aspects of disease to genetic, genomic, or proteomic information gained from analysis of biological samples.
At Truly Labs we have extensive experience with identification and characterisation of biomarkers in preclinical models and how to translate these into clinically relevant biomarkers to support the clinical development. This forms the basis for building your biomarker plan that addresses the critical questions about who to treat, when to treat as well as who is a responder to your drug. It also enables a proper bridging between preclinical and early clinical studies, ensuring that the analytical methods are fit-for-purpose and validated at the right time.
Microscopic studies of tissues allow analysis of cells, proteins and expression profiles in a spatial context. We offer a wide range of services, including histological analysis, multiplexed immunohisto-chemistry, and RNAScope.
Biomarkers are valuable tools to monitor disease progression and treatment efficacy. We customize assays to measure biomarkers supporting dose selection, patient stratification as well as potential liabilities.
Flow cytometry generates quantitative phenotypic maps of cells and their activities in a given tissue at a given time. Protein expression, antibody binding and functional activation can also be studied to support lead selection.
